867331-63-3 (7-(2-氯-5-甲氧基苯基)-5-甲基-N-(4-(2-(吡咯烷-1-基)乙氧基)苯基)苯并[e][1,2,4]噻嗪-3-胺,1,2,4-Benzotriazin-3-aMine, 7-(2-chloro-5-Methoxyphenyl)-5-Methyl-N-[4-[2-(1-pyrrolidinyl)ethoxy]phenyl]-)

CAS号:
867331-63-3
中文名称:
7-(2-氯-5-甲氧基苯基)-5-甲基-N-(4-(2-(吡咯烷-1-基)乙氧基)苯基)苯并[e][1,2,4]噻嗪-3-胺
英文名称:
1,2,4-Benzotriazin-3-aMine, 7-(2-chloro-5-Methoxyphenyl)-5-Methyl-N-[4-[2-(1-pyrrolidinyl)ethoxy]phenyl]-
分子式:
C27H28ClN5O2
分子量:
489.996524810791

7-(2-氯-5-甲氧基苯基)-5-甲基-N-(4-(2-(吡咯烷-1-基)乙氧基)苯基)苯并[e][1,2,4]噻嗪-3-胺(867331-63-3)名称与标识符

名称

中文别名:
7-(2-氯-5-甲氧基苯基)-5-甲基-N-(4-(2-(吡咯烷-1-基)乙氧基)苯基)苯并[E];7-(2-氯-5-甲氧基苯基)-5-甲基-N-(4-(2-(吡咯烷-1-基)乙氧基)苯基)苯并[e][1,2,4]噻嗪-3-胺;
英文别名:
1,2,4-Benzotriazin-3-aMine, 7-(2-chloro-5-Methoxyphenyl)-5-Methyl-N-[4-[2-(1-pyrrolidinyl)ethoxy]phenyl]-;7-(2-Chloro-5-methoxyphenyl)-5-methyl-N-(4-(2-(pyrrolidin-1-yl)ethoxy)phenyl)benzo[e][1,2,4]triazin-3-amine;7-(2-chloro-5-methoxyphenyl)-5-methyl-N-[4-(2-pyrrolidin-1-ylethoxy)phenyl]-1,2,4-benzotriazin-3-amine;7-(2-Chloro-5-methoxyphenyl)-5-methyl-N-[4-[2-(1-pyrrolidinyl)ethoxy]phenyl]-1,2,4-benzotriazin-3-amine (ACI);US8481536, 396;7-(2-Chloro-5-methoxyphenyl)-5-methyl-N-{4-[2-(pyrrolidin-1-yl)ethoxy]phenyl}-1,2,4-benzotriazin-3-amine;DTXSID20647592;DB-307213;BDBM50198821;BCP14239;CS-M1981;CHEMBL394765;AKOS037649682;CS-13272;867331-63-3;SCHEMBL4265021;

标识符

InChIKey:
OJBBZIACVFADED-UHFFFAOYSA-N
Inchi:
1S/C27H28ClN5O2/c1-18-15-19(23-17-22(34-2)9-10-24(23)28)16-25-26(18)30-27(32-31-25)29-20-5-7-21(8-6-20)35-14-13-33-11-3-4-12-33/h5-10,15-17H,3-4,11-14H2,1-2H3,(H,29,30,32)
SMILES:
ClC1C(C2C=C(C)C3C(=NN=C(NC4C=CC(OCCN5CCCC5)=CC=4)N=3)C=2)=CC(OC)=CC=1

7-(2-氯-5-甲氧基苯基)-5-甲基-N-(4-(2-(吡咯烷-1-基)乙氧基)苯基)苯并[e][1,2,4]噻嗪-3-胺(867331-63-3)物化性质

计算特性

  • 精确分子量 : 489.1931528g/mol
  • 氢键供体数量 : 1
  • 氢键受体数量 : 7
  • 可旋转化学键数量 : 8
  • 同位素质量 : 489.1931528g/mol
  • 重原子数量 : 35
  • 复杂度 : 645
  • 同位素原子数量 : 0
  • 确定原子立构中心数量 : 0
  • 不确定原子立构中心数量 : 0
  • 确定化学键立构中心数量 : 0
  • 不确定化学键立构中心数量 : 0
  • 共价键单元数量 : 1
  • 疏水参数计算参考值(XlogP) : 5.6
  • 拓扑分子极性表面积 : 72.4Ų

7-(2-氯-5-甲氧基苯基)-5-甲基-N-(4-(2-(吡咯烷-1-基)乙氧基)苯基)苯并[e][1,2,4]噻嗪-3-胺(867331-63-3)推荐厂家 更多厂家(4)

公司名称手机号/电话联系人QQ微信询单
上海瀚思化工有限公司 18939883912
021-34536277
顾经理 3003949364
询单
上海绩祥生物科技有限公司 13093077543陆经理 3985448220
询单
江苏艾康生物医药研发有限公司 18795912720
025-66061636
杨情情 3004779232
询单
上海吉至生化科技有限公司 18117592386
021-57481218
吉至试剂 3007522982
询单
上海源叶生物科技有限公司 15026964105
15026964105
汤思磊 2881489226
询单

7-(2-氯-5-甲氧基苯基)-5-甲基-N-(4-(2-(吡咯烷-1-基)乙氧基)苯基)苯并[e][1,2,4]噻嗪-3-胺(867331-63-3)合成路线

合成路线:1 步
反应条件:
参考文献:
Discovery of [7-(2,6-dichlorophenyl)-5-methylbenzo [1,2,4]triazin-3-yl]-[4-(2-pyrrolidin-1-ylethoxy)phenyl]amine-a potent, orally active Src kinase inhibitor with antitumor activity in preclinical assays
Noronha, Glenn; et al, Bioorganic & Medicinal Chemistry Letters, 2007, 17(3), 602-608
合成路线:1 步
反应条件:
参考文献:
Development of Prodrug 4-Chloro-3-(5-methyl-3-{[4-(2-pyrrolidin-1-ylethoxy)phenyl]amino}-1,2,4-benzotriazin-7-yl)phenyl Benzoate (TG100801): A Topically Administered Therapeutic Candidate in Clinical Trials for the Treatment of Age-Related Macular Degeneration
Palanki, Moorthy S. S.; et al, Journal of Medicinal Chemistry, 2008, 51(6), 1546-1559
合成路线:2 步
反应条件:
参考文献:
Development of Prodrug 4-Chloro-3-(5-methyl-3-{[4-(2-pyrrolidin-1-ylethoxy)phenyl]amino}-1,2,4-benzotriazin-7-yl)phenyl Benzoate (TG100801): A Topically Administered Therapeutic Candidate in Clinical Trials for the Treatment of Age-Related Macular Degeneration
Palanki, Moorthy S. S.; et al, Journal of Medicinal Chemistry, 2008, 51(6), 1546-1559
合成路线:2 步
反应条件:
参考文献:
Discovery of [7-(2,6-dichlorophenyl)-5-methylbenzo [1,2,4]triazin-3-yl]-[4-(2-pyrrolidin-1-ylethoxy)phenyl]amine-a potent, orally active Src kinase inhibitor with antitumor activity in preclinical assays
Noronha, Glenn; et al, Bioorganic & Medicinal Chemistry Letters, 2007, 17(3), 602-608
合成路线:3 步
反应条件:
参考文献:
Development of Prodrug 4-Chloro-3-(5-methyl-3-{[4-(2-pyrrolidin-1-ylethoxy)phenyl]amino}-1,2,4-benzotriazin-7-yl)phenyl Benzoate (TG100801): A Topically Administered Therapeutic Candidate in Clinical Trials for the Treatment of Age-Related Macular Degeneration
Palanki, Moorthy S. S.; et al, Journal of Medicinal Chemistry, 2008, 51(6), 1546-1559
合成路线:3 步
反应条件:
参考文献:
Discovery of [7-(2,6-dichlorophenyl)-5-methylbenzo [1,2,4]triazin-3-yl]-[4-(2-pyrrolidin-1-ylethoxy)phenyl]amine-a potent, orally active Src kinase inhibitor with antitumor activity in preclinical assays
Noronha, Glenn; et al, Bioorganic & Medicinal Chemistry Letters, 2007, 17(3), 602-608
合成路线:4 步
反应条件:
参考文献:
Development of Prodrug 4-Chloro-3-(5-methyl-3-{[4-(2-pyrrolidin-1-ylethoxy)phenyl]amino}-1,2,4-benzotriazin-7-yl)phenyl Benzoate (TG100801): A Topically Administered Therapeutic Candidate in Clinical Trials for the Treatment of Age-Related Macular Degeneration
Palanki, Moorthy S. S.; et al, Journal of Medicinal Chemistry, 2008, 51(6), 1546-1559
合成路线:4 步
反应条件:
参考文献:
Discovery of [7-(2,6-dichlorophenyl)-5-methylbenzo [1,2,4]triazin-3-yl]-[4-(2-pyrrolidin-1-ylethoxy)phenyl]amine-a potent, orally active Src kinase inhibitor with antitumor activity in preclinical assays
Noronha, Glenn; et al, Bioorganic & Medicinal Chemistry Letters, 2007, 17(3), 602-608